Investigational drugs for Diabetic nephropathy

Monica Cortinovis, Dario Cattaneo, Norberto Perico, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review


Background: Diabetic nephropathy is one of the main causes of end-stage renal disease (ESRD) and is associated with elevated cardiovascular morbidity and mortality. Objective: Current renoprotective treatments for diabetic nephropathy include strict glycemic and optimal blood pressure control, proteinuria/ albuminuria reduction and the use of renin-angiotensin-aldosterone system (RAAS) blocking agents. However, the renoprotection provided by these treatments is only partial, calling for more effective approaches. Methods: This review examines emerging strategies for the treatment of diabetic nephropathy, including aggressive RAAS blockade, statins, glitazones, ruboxistaurin, and other promising agents. Results/conclusions: In diabetic patients with overt nephropathy, multipharmacological interventions represent a promising way to prevent progression to ESRD. Results of ongoing trials are needed to estblish whether the current standard of care of diabetic nephropathy might be improved with these new strategies.

Original languageEnglish
Pages (from-to)1487-1500
Number of pages14
JournalExpert Opinion on Investigational Drugs
Issue number10
Publication statusPublished - Oct 2008


  • Chronic kidney disease
  • Diabetic nephropathy
  • Renin-angiotensin-aldosterone system
  • Renoprotective agents

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Investigational drugs for Diabetic nephropathy'. Together they form a unique fingerprint.

Cite this